

Dear Author,

This manuscript have a great collecting data about this topic.

Point:

1. Because your eligible study was all randomized controlled trials I think you can add “randomized trial” in the title

[Author Response: Thank you, we have added randomized trials to the title]

2. Could you add the short introduction about the background knowledge about adverse effects in GLP-1 receptor agonist and DPP inhibitor drugs

[Author Response: Thank you, we have added a short sentence as suggested: “As GLP-1 is a gut hormone, it is possible that patients may experience adverse effects on the gastrointestinal system such as nausea or abdominal pain.”]

3. Are there any explanation about pancreatic cancer risk in previous literature and more discussion about this issue in your manuscript

[Author Response: Thank you, we have added this short sentence as suggested: “It is also unclear whether the inflammatory process from recurrent or chronic pancreatitis is a predisposing factor to subsequent development of pancreatic cancer.”]

4. About the relationship of pancreatic enzyme elevation and pancreatitis in the literature. Did they use the same definition of acute pancreatitis in each publications?

[Author Response: Thank you, we have added this short sentence as suggested:” Moreover, the included studies did not specify whether they applied similar criteria in defining cases of pancreatitis.”]